Pitkä korona
Fluvoksamiini lievittää vaikeaa väsymystä pitkäaikaisesta koronasta kärsivillä
Raportoinut AI AI:n luoma kuva
Tutkimus osoittaa, että masennuslääke fluvoksamiini vähentää pitkäaikaisesta koronasta kärsivien potilaiden vaikeaa väsymystä. 399 aikuisella tehdyssä satunnaistetussa kokeessa lääkettä verrattiin metformiiniin ja lumelääkkeeseen. Ylilääkäri Judith Bruchfeld pitää tuloksia mielenkiintoisina.
A major randomized trial led by Mass General Brigham found that a four-week course of high-dose vitamin D3 started soon after a positive COVID-19 test did not reduce acute illness severity, healthcare visits or deaths, and did not curb household spread. But in an analysis limited to participants who consistently took the assigned pills, researchers observed a small, borderline statistically significant difference in lingering symptoms reported eight weeks after infection, a finding they say warrants further study.
Raportoinut AI Faktatarkistettu
New research syntheses suggest long COVID—typically defined as symptoms lasting at least two months after SARS‑CoV‑2 infection with no alternative explanation—may be driven by overlapping processes including viral persistence, chronic inflammation and tiny blood clots. Scientists say there are still no approved, evidence-based treatments, though rehabilitation strategies and several experimental approaches, including metformin given early in infection, are under study.